Entrada Therapeutics, Inc. announced that Nathan J. Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024. Nate joined Entrada in 2019 and has 30 years of strategy, investment, and operational experience in the healthcare sector. He has played a critical role in developing Entrada?s strategic and operational capabilities, helping to scale the Company to over 150 employees and advance its lead program, ENTR-601-44, into the clinic.

Prior to Entrada, Nate served as Senior Vice President of Corporate Development at Rubius Therapeutics, where he supported the organization?s evolution from an early-stage discovery company into a clinical development organization. He also spent 16 years in Managing Director roles at the Huron Consulting Group and The Frankel Group LLC advising biotechnology, biopharmaceutical, diagnostic, and medical device companies. Prior experience also included time with EY and CIGNA Healthcare.

Nate holds an MBA from the Booth School of Business at the University of Chicago and a BS from the University of Connecticut.